Edition:
United States

Albireo Pharma Inc (ALBO.OQ)

ALBO.OQ on NASDAQ Stock Exchange Capital Market

32.61USD
20 Jul 2018
Change (% chg)

-- (--)
Prev Close
$32.61
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
33,814
52-wk High
$39.67
52-wk Low
$20.27

Chart for

About

Albireo Pharma, Inc., formerly Biodel Inc., is a specialty biopharmaceutical company. It is focused on the development and commercialization of bile acid modulators to treat orphan pediatric liver diseases and gastrointestinal (GI), disorders where improper flow or absorption of bile causes serious medical conditions for which... (more)

Overall

Beta: 1.27
Market Cap(Mil.): $388.71
Shares Outstanding(Mil.): 11.94
Dividend: --
Yield (%): --

Financials

  ALBO.OQ Industry Sector
P/E (TTM): -- 217.69 33.34
EPS (TTM): -2.21 -- --
ROI: -16.34 -3.65 13.18
ROE: -20.23 -5.62 15.09

BRIEF-Albireo Qtrly Net Loss Per Share - Basic And Diluted $0.15

* ALBIREO PHARMA INC - QTRLY NET LOSS PER SHARE - BASIC AND DILUTED $0.15 Source text for Eikon: Further company coverage: (Reuters.Briefs@thomsonreuters.com)

May 17 2018

BRIEF-Albireo Enrolls First Patient In Phase 3 PFIC Trial Of A4250

* ALBIREO ENROLLS FIRST PATIENT IN PHASE 3 PFIC TRIAL OF A4250 Source text for Eikon: Further company coverage:

May 16 2018

BRIEF-Albireo Pharma Inc Files For Non-Timely 10-K ‍​

* ALBIREO PHARMA INC FILES FOR NON-TIMELY 10-K WITH THE U.S. SEC ‍​ Source text: (http://bit.ly/2pobWiJ) Further company coverage:

Mar 19 2018

BRIEF-Albireo Reports Fourth Quarter And Year-End 2017 Financial Results

* ALBIREO REPORTS FOURTH QUARTER AND YEAR-END 2017 FINANCIAL RESULTS

Mar 15 2018

BRIEF-Albireo Prices $65.0 Mln Public Offering Of Common Stock

* ALBIREO PRICES $65.0 MILLION PUBLIC OFFERING OF COMMON STOCK

Jan 25 2018

Earnings vs. Estimates